MGTX News and Press, MeiraGTx Holdings plc From 06/17/19

Biotech Pulse Biotech shares are up this year, as represented by the Nasdaq Biotechnology Index ( IBB ), which is the industry benchmark, and the S&P Select Biotechnology Index ( XBI ), after a sharp decline in 2018. This is a welcome respite for biotech investors. However, it has not ...

Market Pulse The month of May thus far has been mostly a downward ride with an occasional rise, proving to be a mere bunny bump, as indexes have eroded persistently on the lack of a trade resolution with China, an outcome that at one point was considered to be almost in the bag. This is rais...

Biotech Pulse The Nasdaq Biotech ( IBB ) and the S&P Biotech ( XBI ) indexes have struggled since March as the broader healthcare sector ( XLV ) declined following growing momentum amongst the presidential candidates for a universal healthcare plan. This was at a time when the broader ma...

The iShares Russell 2000 ETF ( IWM ) tracks a basket of small-cap stocks including companies not typically part of large-cap broad market indexes like the S&P 500. Year to date, the ETF is up 15%, but still 10% below its all-time high set in August of 2018, which is in contrast to the S&am...

Gainers:  Big 5 Sporting Goods (NASDAQ: BGFV ) +26% . Novavax (NASDAQ: NVAX ) +25% . Asta Funding (NASDAQ: ASFI ) +20% . MeiraGTx Holdings (NASDAQ: MGTX ) +19% . Luokung Technology (NASDAQ: LKCO ) +18% . Key Energy Services (NYSE: KEG ) +17% . Verastem (NASDAQ: VSTM ) +17% . Su...

Preliminary data from a 15-subject Phase 1/2 clinical trial evaluating MeiraGTx Holdings' (NASDAQ: MGTX ) gene therapy AAV-RPE65 for the treatment of an inherited disorder that can lead to blindness called RPE65 deficiency showed a positive effect. More news on: MeiraGTx Holdings plc, He...

MeiraGTx (NASDAQ: MGTX ): Q1 GAAP EPS of -$0.62 beats by $0.02 . More news on: MeiraGTx Holdings plc, Earnings news and commentary, Healthcare stocks news, Read more ...

• Positive 6-month results from Phase 1/2 clinical trial of AAV-RPE65 • Enrollment completed in the Phase 1/2 clinical trial investigating AAV-CNGB3 gene therapy for the treatment of achromatopsia LONDON and NEW YORK, May 14, 2019 (GLOBE NEWSWIRE) -- Me...

AAV-RPE65 met the primary endpoint of safety and tolerability Statistically significant improvement demonstrated in vision-guided mobility and visual function in treated eyes compared to untreated eyes Dose selected for pivotal study; Company expects to meet with global regulatory ...

LONDON and NEW YORK, May 06, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will present at the BAML Healthc...